News

A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the ...
A federal judge has rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's ...
Shares of Scholar Rock Holding ( SRRK 13.36%) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 ...
Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body ...
Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve more lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound.
Scholar Rock said its investigational therapy helped preserve lean mass among patients taking a powerful weight loss drug.
It wasn't so long ago that Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company, seemed to be firing on all cylinders. CagriSema, an investigational weight loss medicine, performed well in ...